US Patent 12,414,942 (Aceclidine) presbyopia: scope, claim map, and US patent landscape
US Patent 12,414,942 is directed to a two-instillation dosing regimen for treating presbyopia using aceclidine (or a salt), with (i) a fixed inter-dose gap of about 2 minutes, (ii) defined concentration language (about 1.44 wt.% free base) in dependent claims, and (iii) functional clinical readouts tied to early and longer-duration improvement, plus constraints on preservative-free formulation and limiting dosing to one “first and second drop” set per day. The effective claim core is the combination of aceclidine ophthalmic composition and an inter-drop timing structure that is reinforced by performance criteria (3 lines within 0.5 hours and 3 lines for at least 8 hours).
What claims does US Patent 12,414,942 have for aceclidine eye drops for presbyopia?
Claim set overview (independent + dependent coverage)
The patent includes one independent method claim (claim 1) and three independent method claims (claims 1–4 are drafted as independent families in your excerpt; claims 5–16 are dependent refactors). The claim architecture uses the same dosing scaffold and narrows by (a) efficacy window, (b) preservative-free, (c) maximum drops per day, and (d) aceclidine concentration.
Independent claim 1: two drops with ~2-minute spacing and aceclidine concentration (free base ~1.44 wt.%)
Core limitations
- Treat presbyopia in an individual.
- Administer a first ophthalmic “drop of an ophthalmological composition” to an eye.
- Subsequently administer a second drop to the eye.
- The second drop is about 2 minutes after the first.
- The composition comprises aceclidine or a salt thereof.
- The composition comprises aceclidine in a free base concentration of about 1.44 wt.%.
Scope effect
- Claim 1 anchors the patent around a specific formulation strength plus a timed two-drop regimen.
- “About 2 minutes” and “about 1.44 wt.%” preserve some variability, which makes the literal boundary depend on prosecution history, claim construction, and the patent’s description.
Independent claim 2: performance-based claim tied to timing of effect
Core limitations
- Same two-drop regimen as claim 1: first drop, second drop about 2 minutes later, aceclidine (or salt).
- Adds two efficacy criteria:
- 3-lines or more improvement within 0.5 hours of administering the second drop.
- 3-lines or more improvement for at least 8 hours.
Scope effect
- The claim shifts from concentration emphasis to clinical performance tied to timepoints relative to the second instillation.
- This can capture product concepts even if the aceclidine concentration is not stated in the independent claim text (unless the written description ties 2 to a specific concentration elsewhere and the court construes functional limitations as requiring congruence).
Independent claim 3: preservative-free + two drops in each eye with ≥10 hours effect
Core limitations
- Instill one drop in each eye, then a second drop in each eye about 2 minutes later.
- “For an effect of at least 10 hours.”
- The ophthalmological composition is preservative-free.
- Aceclidine (or salt) is included in the composition.
Scope effect
- Preservative-free is an explicit formulation constraint.
- The effect duration threshold (“at least 10 hours”) is broader than claim 2’s “at least 8 hours” line improvement and may be argued as different metrics (functional lines vs. duration of effect).
- The claim uses “in each eye,” which can exclude a design that treats one eye at a time or uses unilateral instillation.
Independent claim 4: preservative/dosing-frequency constraints simplified as “no more than two drops per day”
Core limitations
- Instill one drop in each eye, second drop about 2 minutes later.
- “For an effect of at least 10 hours.”
- Aceclidine (or salt) in the composition.
- No more than a first drop and a second drop administered to the eye in a day (one dosing cycle per day).
Scope effect
- This is a frequency/daily maximum constraint, limiting dosing schedules that use more than one two-drop cycle per day.
How do the dependent claims narrow the scope of US 12,414,942?
Dependent claims (5–16) mainly “stack” qualifiers onto the base two-drop regimen.
Efficacy reinforcement (claims 5 and 12)
- Claim 5: adds the claim 2 line-improvement/timepoint requirements to claim 1.
- Claim 12: adds the claim 2 line-improvement/timepoint requirements to claim 2’s chain (your excerpt states it as “The method of claim 2” but it functionally re-articulates the same two-line/time thresholds).
Scope effect:
- Reinforces that the patent estate can be asserted under a performance/endpoint theory.
Preservative-free reinforcement (claims 6, 9, and 16)
- Claim 6: preservative-free tied to claim 1.
- Claim 9: preservative-free tied to claim 2.
- Claim 16: preservative-free tied to claim 4.
Scope effect:
- Supports infringement arguments for formulation teams using preservative-free packaging or composition.
Daily maximum dosing (claims 7, 10, and 13)
- Claim 7: daily constraint tied to claim 1.
- Claim 10: daily constraint tied to claim 2.
- Claim 13: daily constraint tied to claim 3.
Scope effect:
- Supports “labeling and regimen” enforcement where generic or branded competitors attempt a different daily dosing frequency.
Aceclidine concentration reinforcement (claims 8, 11, and 14)
- Claim 8: concentration about 1.44 wt.% free base tied to claim 2.
- Claim 11: concentration tied to claim 3.
- Claim 14: concentration tied to claim 4.
Scope effect:
- Concentration-limited dependent claims create multiple independent legal hooks even if a defendant tries to argue the main independent claim avoids a concentration number.
What is the claim “center of gravity” for US 12,414,942 infringement risk?
Center of gravity (literal and practical):
- Aceclidine (or salt) ophthalmic composition for presbyopia
- Two-drop regimen
- Inter-dose timing: about 2 minutes
- Performance evidence (3 lines within 0.5 hours of second drop; 3 lines for at least 8 hours; and/or at least 10 hours effect)
- Formulation constraints: preservative-free
- Regimen constraints: one dosing cycle per day
Highest-risk design-around surfaces
- Timing: moving the inter-drop gap materially away from “about 2 minutes.”
- Dose cycle: adding a second dosing cycle per day (could violate “no more than…” language).
- Preservative status: adding preservatives likely leaves fewer of the patent’s formulation-limited claims available.
- Endpoint strategy: if a competitor uses different efficacy endpoints, they still face infringement if the claimed functional outcomes are met (or if the claim construction reads the endpoints as results to be expected at administration).
What formulations are protected: preservative-free and aceclidine concentration at 1.44 wt.% free base?
Aceclidine concentration (about 1.44 wt.% free base)
Claims 1, 8, 11, and 14 contain concentration-dependent limitations. That creates two practical issues for competitors:
- If a competitor’s formulation is not “about 1.44 wt.%,” literal infringement may be harder for those concentration-dependent claims.
- But claim 2 and claim 3/4 pathways may still be asserted under the performance and dosing regimen elements, depending on how “composition comprising aceclidine or a salt” is construed against the rest of the spec.
Preservative-free
Claims 3, 4, and dependent claims 6, 9, 16 lock in preservative-free. This is often a product-manufacturing and packaging design constraint (single-use units, preservative-free bottle systems, etc.).
Which dosing regimens does US 12,414,942 cover for presbyopia?
Regimen geometry
- First drop: into the eye (or “each eye” in claims 3 and 4)
- Second drop: after about 2 minutes
- Daily maximum: no more than a single first+second drop set per eye/day (claim 4 pathway via dependent claim 7 and claim 10/13)
- Efficacy timepoints:
- onset: 3 lines or more within 0.5 hours after the second drop (claims 2/5/12)
- duration: 3 lines or more for at least 8 hours (claims 2/5/12)
- overall effect: at least 10 hours (claims 3/4 and dependent recitations)
Operational implication for product labeling
A competitor’s label that describes a substantially identical two-drop sequence and timing can be tested against the claimed method, even if formulation variables differ, depending on how the court construes “about” ranges and whether the required endpoints are achieved.
How strong is the patent estate for US 12,414,942 based on claim scope breadth?
Claim strength indicators
- The invention is not only “aceclidine for presbyopia” but “aceclidine + sequential dosing with a specific inter-drop interval.”
- The claims incorporate measurable clinical outcomes tied to timepoints and duration, which can support enforceability through clinical evidence.
Claim vulnerability indicators (within the excerpted claim language)
- The concentration language is specific in dependent claims, which can create a factual defense where competitors choose alternative aceclidine strengths outside “about 1.44 wt.%.”
- The preservative-free limitations create a formulation escape hatch for preservative-included concepts, though the independent claims’ structure depends on whether the claims asserted are the preservative-free ones or the broader ones.
Practical enforcement posture
- Most favorable enforcement for a patentee: assert the claims that align with how the reference product is actually used (two-drop about 2 minutes; preservative-free; once per day; endpoint meets 3 lines and duration).
- For a defendant: emphasize differences in inter-dose timing, daily cycle, preservatives, and concentration, and attack clinical equivalence.
What are the key design-around options against this claim set?
Based on the claim elements in the excerpt, the highest-leverage switches are:
- Inter-dose interval: move from “about 2 minutes” to a materially different timing (earlier or later) so the method no longer reads on “about 2 minutes.”
- Dosing frequency: exceed the “no more than first and second drop… in a day” limitation to step outside claims that include that constraint, while still evaluating other claims without the frequency limitation.
- Preservative status: if the relevant claims require preservative-free, introduce a preservative system or use a different formulation strategy to avoid preservative-free coverage.
- Concentration: choose aceclidine free-base concentration outside “about 1.44 wt.%” to avoid concentration-dependent dependent claims.
What is the US regulatory/IP enforcement interface for this type of presbyopia eye-drop patent?
For method-of-treatment patents and ophthalmic dosing regimens, enforcement typically tracks:
- Orange Book listing mechanics (for drug product patents tied to FDA-approved products)
- Method patents enforcement through “use” of a label-described regimen
- Litigation posture around whether the proposed generic/biosimilar-like product’s labeling induces infringement
This excerpt alone does not identify Orange Book listing status, NDA/BLA number, or drug product identity, so no determination can be made regarding the patent’s listing mechanics in the US.
How does US 12,414,942 compare with other presbyopia aceclidine or ophthalmic regimen patents?
A full landscape comparison requires the broader US-family dataset: continuation/pipeline claims, related US patents in the same family, and competitor aceclidine ophthalmic presbyopia method patents. The provided material includes only the claims of US 12,414,942, not the family set, assignee network, or competitor identifiers; a comparative landscape table cannot be constructed from the excerpt.
Claim-by-claim infringement checklist (what an accused product/regimen must do)
Claims 1/5/8/11/14: timing + aceclidine + ~1.44 wt.% free base
- Uses aceclidine (or salt) ophthalmic composition for presbyopia
- Administers two drops to the eye with about 2-minute spacing
- Achieves aceclidine free base concentration about 1.44 wt.% (or within claim construction for “about”)
- For claims that also add performance criteria (claims 5), achieves at least 3 lines improvement within 0.5 hours after the second drop and at least 3 lines for at least 8 hours
Claims 2/9/10/12: timing + aceclidine + clinical endpoint/time window
- Same two-drop regimen with about 2-minute spacing
- Prescribed/achieved outcomes:
- ≥3-line improvement within 0.5 hours after second drop
- ≥3-line improvement for ≥8 hours
- Claim 9 adds preservative-free (if asserted)
- Claim 10 adds daily maximum dosing (if asserted)
Claims 3/6/13/16: two drops in each eye + preservative-free + ≥10-hour effect
- One drop in each eye, then second drop in each eye about 2 minutes later
- Preservative-free composition
- Effect duration at least 10 hours
Claims 4/7/15: two drops in each eye + ≥10-hour effect + daily maximum
- One drop in each eye, then second drop in each eye about 2 minutes later
- Effect at least 10 hours
- No more than one two-drop dosing cycle per eye per day
- Claim 15 adds the 3-lines within 0.5 hours and 3-lines for at least 8 hours requirements if asserted as recited
Key Takeaways
- Primary patented method: presbyopia treatment using aceclidine ophthalmic drops with a two-instillation regimen where the second drop is administered about 2 minutes after the first.
- Most enforceable combination elements: timing + aceclidine + clinical endpoints (3 lines within 0.5 hours after second drop; 3 lines for at least 8 hours) and/or durational effect (at least 10 hours).
- Key product-design risk factors: aceclidine free-base concentration ~1.44 wt.% (dependent claims), preservative-free status, and once-per-day maximum dosing structure.
- Design-arounds with the strongest potential to avoid claim coverage (per the excerpt): materially changing inter-dose timing away from “about 2 minutes,” moving to preservative-included formulations (where preservative-free is required), changing aceclidine concentration outside “about 1.44 wt.%,” and altering daily dosing frequency beyond the “no more than first and second drop… in a day” limitation.
FAQs
- What does “about 2 minutes” mean for a two-drop presbyopia regimen under US 12,414,942?
- Do the performance-based line-improvement limitations require the claims to specify a particular visual acuity test (for infringement and evidence)?
- Can a preservative-containing aceclidine formulation still infringe if a method claim does not include “preservative-free”?
- How does the “at least 10 hours” effect standard in claims 3/4 differ from the “3 lines for at least 8 hours” standard in claim 2?
- If a competitor uses a different daily dosing schedule, which dependent claims in US 12,414,942 become the main infringement focus?
References
No external sources were cited because no dossier data (publication number, family members, prosecution history, assignee, examiner, related patents, Orange Book entries, FDA application identifiers, or litigation records) was provided beyond the claim text.
